In conclusion, our meta-analysis suggests that IBD-CRC and S-CRC may have different molecular pathways given the higher prevalence of TP53 but lower prevalence of KRAS mutation in the patients with IBD-CRC compared to S-CRC. This evidence concerns the gene KRAS and colorectal carcinoma.